Regulatory PathRegulatory requirements compared

Active substance

Ensifentrine

Open in the medicines table

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
OHTUVAYRE3MG/2.5MLsuspension · inhalationMSDPrescription26 Jun 2024

EMA European Union — centrally authorised medicines

Ohtuvayre Verona Pharma Ireland Limited · Application withdrawn · ATC R03BX

Therapeutic indication (EMA)

Maintenance treatment in symptomatic adult patients with chronic obstructive pulmonary disease (COPD).

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.